Celularity Inc CELUW Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001641172-25-009319
cik 1752828
name CELULARITY INC
sic 2834
countryba US
stprba NJ
cityba FLORHAM PARK
zipba 07932
bas1 170 PARK AVE
bas2
baph (908) 768-2170
countryma US
stprma NJ
cityma FLORHAM PARK
zipma 07932
mas1 170 PARK AVE
mas2
countryinc US
stprinc DE
ein 831702591
former GX ACQUISITION CORP.
changed 20180912
afs 4-NON
wksi 0
fye 1231
form 10-K
period 20241231
fy 2024
fp FY
filed 20250508
accepted 2025-05-08 17:29:00.0
prevrpt 0
detail 1
instance form10-k_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001641172-25-009319 20231231 Accounts Payable Current 14144000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Accrued Liabilities And Other Liabilities 1274.0000 USD 0 us-gaap/2024 Related Party Transaction= Dr Robert Hariri;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Issuance And Modification Of Warrants 3261000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability Classified To Equity Classified USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 11569000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 11569000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Allowance For Doubtful Accounts Receivable Current 6294000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Asset Acquisition Contingent Consideration Liability 1606000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Asset Acquisition Contingent Consideration Liability Current USD 0 us-gaap/2024
0001641172-25-009319 20231231 Common Stock Shares Issued 19378192.0000 shares 0 us-gaap/2024
0001641172-25-009319 20231231 Common Stock Value 19000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Common Stock Value 2000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Contract With Customer Liability Noncurrent 3186000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Cost Of Revenue 16016000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Cost Of Revenue 13817000.0000 USD 4 us-gaap/2024 Business Segments= Degenerative Disease;
0001641172-25-009319 20241231 Depreciation Depletion And Amortization 7922000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Earnings Per Share Diluted -11.0200 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Earnings Per Share Diluted -2.6400 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Gains Losses On Extinguishment Of Debt USD 4 us-gaap/2024
0001641172-25-009319 20241231 Gains Losses On Extinguishment Of Debt -3908000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Goodwill Impairment Loss USD 4 us-gaap/2024
0001641172-25-009319 20241231 Intangible Assets Net Excluding Goodwill 9248000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Inventory Impairment Charge 466000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Issuance Of Common Stock Relating To Debt Extension And Commitment Fee 712000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Net Income Loss -196295000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent -5000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Other Nonoperating Income Expenses -6290000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 P I P E Related Costs Included In Accrued Expenses -69000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 P I P E Related Costs Included In Accrued Expenses USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Proceeds From Convertible Note -2175000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20230331 Proceeds From Issuance Of Private Placement 9000000.0000 USD 0 us-gaap/2024 Equity Components= March Two Thousand Twenty Three Private Investment In Public Equity Warrants;
0001641172-25-009319 20241231 Proceeds From Warrants And Short Term Debt Related Parties 15000000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Reclassification Of Warrants From Liability Classified To Equity Classified USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Repayments Of Short Term Debt Related Party 146000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Retained Earnings Accumulated Deficit -841791000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Revenue From Contract With Customer Excluding Assessed Tax 5441000.0000 USD 4 us-gaap/2024 Business Segments= Biobanking;
0001641172-25-009319 20231231 Shares Outstanding 19378192.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Short Term Borrowings 2485000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-009319 20231231 Shortterm Debt Fair Value USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001641172-25-009319 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 1700000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value Of Research And Development USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures 0.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Issued During Period Value Share Based Compensation 158000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value Stock Options Exercised USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Issuance And Modification Of Warrants USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Accounts And Other Receivables Net Current 10046000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Accrued Research And Development Software USD 0 0001641172-25-009319
0001641172-25-009319 20231231 Accumulated Other Comprehensive Income Loss Net Of Tax USD 0 us-gaap/2024
0001641172-25-009319 20241231 Adjustments Related To Tax Withholding For Share Based Compensation 434000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability Classified To Equity Classified USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 15017000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Amortization Of Intangible Assets 1753000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Assumption Of Shortterm Debt Unaffiliated By Related Party 2333000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 -193000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Capital Expenditures Incurred But Not Yet Paid 87000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 10163000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 10977000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0001641172-25-009319 20241231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20241231 Common Stock Shares Outstanding 22546671.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20231231 Comprehensive Income Net Of Tax -196149000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Conversion Of Stock Amount Issued1 4599000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Cost Of Revenue 14366000.0000 USD 4 us-gaap/2024 Business Segments= Degenerative Disease;
0001641172-25-009319 20241231 Deferred Income Tax Liabilities Net 9000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Employee Benefits And Share Based Compensation 11569000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Fair Value Adjustment Of Warrants -398000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Fair Value Of Warrant Modification For Professional Service 403000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Fair Value Of Warrant Modification For Professional Service 403000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Impairment Of Intangible Assets Excluding Goodwill 107800000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Income Tax Expense Benefit USD 4 us-gaap/2024
0001641172-25-009319 20231231 Increase Decrease In Accounts Receivable 6827000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Accrued Research Development Software Expense -3500000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Interest Accrued On Senior Secured Loans Within Long Term Debt Related Parties USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Inventory Acquired In Connection With Rebound Asset Acquisition 2150000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Inventory Impairment Charge 5384000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Inventory Net 5753000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Issuance Of Common Stock As Compensation Expense 158000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Issuance Of Common Stock As Consideration For Settlement Agreement USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Issuance Of Common Stock Relating To Debt Extension And Commitment Fee 317000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Net Income Loss -57892000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Operating Lease Right Of Use Asset 10830000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent -5000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -5000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Other Liabilities Noncurrent 280000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Other Nonoperating Expense 3015000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Other Nonoperating Income 320000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001641172-25-009319 20230531 Proceeds From Issuance Of Private Placement 3750000.0000 USD 0 us-gaap/2024 Equity Components= May Two Thousand Twenty Three Private Investment In Public Equity Warrants;
0001641172-25-009319 20231231 Proceeds From Issuance Of Private Placement 6000000.0000 USD 0 us-gaap/2024 Class Of Warrant Or Right= January Two Thousand Twenty Four Pipe Warrants; Subsidiary Sale Of Stock= Private Placement;
0001641172-25-009319 20241231 Proceeds From Short Term Debt Unaffiliated 3622000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Reduction Of Right Of Use Assets And Associated Lease Liability Due To Lease Modification USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Repayments Of Short Term Debt Unaffiliated 16811000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Restricted Cash Noncurrent 14722000.0000 USD 0 us-gaap/2024 Business Acquisition= Legacy Celularity; Geographical= Florham Park New Jersey; Property Plant And Equipment By Type= Office Manufacturing And Laboratory Space;
0001641172-25-009319 20231231 Revenue From Contract With Customer Excluding Assessed Tax 17330000.0000 USD 4 us-gaap/2024 Business Segments= Degenerative Disease;
0001641172-25-009319 20231231 Revenue From Contract With Customer Excluding Assessed Tax 4181000.0000 USD 4 us-gaap/2024 Product Or Service= License Royalty And Other;
0001641172-25-009319 20231231 Revenue From Contract With Customer Excluding Assessed Tax 13149000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001641172-25-009319 20241231 Revenue From Contract With Customer Excluding Assessed Tax 5140000.0000 USD 4 us-gaap/2024 Business Segments= Biobanking;
0001641172-25-009319 20241231 Selling General And Administrative Expense 58643000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Shortterm Debt Fair Value 17223000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Shortterm Debt Fair Value 17223000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001641172-25-009319 20231231 Shortterm Debt Fair Value 17223000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001641172-25-009319 20221231 Stockholders Equity 9000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Stockholders Equity 40960000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Stockholders Equity 908523000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Shares A T M Agreement 13296.0000 shares 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value A T M Agreement USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Issued During Period Value Consideration For Settlement Agreement USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value Conversion Of Convertible Securities USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Value For Debt Extension And Commitment Fee USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Stock Issued During Period Value Of Research And Development 1000000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Stock Issued During Period Value Of Research And Development 1000000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024
0001641172-25-009319 20241231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Stock Issued During Period Value Share Based Compensation 158000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Stock Issued During Period Value Stock Options Exercised 58000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Stock Issued During Period Value Stock Options Exercised USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Repurchased And Retired During Period Value -17000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Accrued Liabilities And Other Liabilities 7580000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Accumulated Other Comprehensive Income Loss Net Of Tax -5000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Acquired In Process Research And Development 3000000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Acquired In Process Research And Development USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Additional Paid In Capital 882732000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Adjustments Related To Tax Withholding For Share Based Compensation USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Allowance For Doubtful Accounts Receivable Current 5837000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Amortization Of Intangible Assets 2193000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Asset Acquisition Contingent Consideration Liability 1413000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Assets Current 20561000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -18639000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Change In Fair Value Of Debt 1177000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20231231 Common Stock Shares Outstanding 19378192.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20241231 Comprehensive Income Net Of Tax -57897000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Contingent Consideration Accrued In Connection With Rebound Asset Acquisition 650000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Contract With Customer Liability Current 2834000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Contract With Customer Liability Current 3531000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Cost Of Revenue 1650000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001641172-25-009319 20241231 Cost Of Revenue USD 4 us-gaap/2024 Business Segments= Cell Therapy;
0001641172-25-009319 20231231 Deferred Income Tax Liabilities Net 9000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Employee Benefits And Share Based Compensation 211000.0000 USD 4 us-gaap/2024 Award Type= Market Condition Stock Unit;
0001641172-25-009319 20241231 Goodwill 7347000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Other Accounts Payable And Accrued Liabilities 12634000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Increase Decrease In Prepaid Deferred Expense And Other Assets -5606000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Interest Paid Net 1073000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Interest Paid Net 144000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Inventory Impairment Charge 3255000.0000 USD 4 0001641172-25-009319 Public Utilities Inventory= Inventory Work In Progress;
0001641172-25-009319 20231231 Issuance Of Rwi Warrants In Connection With Forbearance USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Liabilities Current 67298000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Nonoperating Income Expense -3998000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent -5000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent 146000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Other Nonoperating Expense 6264000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Payment Of Sepa Commitment Fee USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Payments Related To Tax Withholding For Share Based Compensation 101000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Payments To Acquire In Process Research And Development 3000000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Payments To Acquire In Process Research And Development USD 4 us-gaap/2024
0001641172-25-009319 20231231 Payments To Acquire Property Plant And Equipment 1048000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001641172-25-009319 20230331 Proceeds From Issuance Of Private Placement 9000000.0000 USD 0 us-gaap/2024 Equity Components= March Two Thousand Twenty Three Private Investment In Public Equity Warrants; Title Of Individual= Dr Robert Hariri; Type Of Arrangement= Securities Purchase Agreement;
0001641172-25-009319 20241231 Promissory Notes Receivable USD 0 0001641172-25-009319
0001641172-25-009319 20231231 Provision For Inventory Obsolescence 1328000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Provision For Inventory Obsolescence -186000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Revenue From Contract With Customer Excluding Assessed Tax 48392000.0000 USD 4 us-gaap/2024 Business Segments= Degenerative Disease;
0001641172-25-009319 20241231 Revenue From Contract With Customer Excluding Assessed Tax 13744000.0000 USD 4 us-gaap/2024 Product Or Service= License Royalty And Other;
0001641172-25-009319 20231231 Selling General And Administrative Expense 50576000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20221231 Short Term Borrowings 37603000.0000 USD 0 us-gaap/2024 Line Of Credit Facility= Yorkville;
0001641172-25-009319 20231231 Shortterm Debt Fair Value USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001641172-25-009319 20221231 Stockholders Equity 198901000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20221231 Stockholders Equity 15000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stockholders Equity 882732000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Stock Issued During Period Shares Consideration For Settlement Agreement 60584.0000 shares 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Shares For Debt Extension And Commitment Fee 116964.0000 shares 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Shares Short Term Debt Maturity Extension 270731.0000 shares 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Shares Stock Options Exercised 20744.0000 shares 4 us-gaap/2024 Plan Name= Two Thousand And Twenty One And Two Thousand And Seventeen Equity Incentive Plan;
0001641172-25-009319 20231231 Stock Issued During Period Value A T M Agreement USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value A T M Agreement USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value Consideration For Settlement Agreement USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 4444000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 1000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value Conversion Of Convertible Securities USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value P I P E Offering Net Of Offering Expenses USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value Stock Options Exercised USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Weighted Average Number Of Shares Outstanding Basic 21890518.0000 shares 4 us-gaap/2024
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition 15017000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Change In Fair Value Of Contingent Stock Consideration -159000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Change In Fair Value Of Debt 492000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class A; Class Of Warrant Or Right= January Two Thousand Twenty Four Pipe Warrants; Subsidiary Sale Of Stock= Private Placement;
0001641172-25-009319 20241231 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001641172-25-009319 20240229 Common Stock Shares Authorized 10000.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A; Counterparty Name= Yorkville; Equity Components= Standby Equity Purchase Agreement;
0001641172-25-009319 20241231 Common Stock Shares Issued 22546671.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20231231 Cost Of Revenue 1650000.0000 USD 4 us-gaap/2024 Business Segments= Biobanking;
0001641172-25-009319 20231231 Fair Value Adjustment Of Warrants -6164000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Fair Value Of Warrant Modification For Professional Service USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20230331 Goodwill Impairment Loss 29633000.0000 USD 1 us-gaap/2024 Business Segments= Cell Therapy;
0001641172-25-009319 20231231 Goodwill Impairment Loss 112347000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Contract With Customer Liability 235000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Increase Decrease In Other Accounts Payable And Accrued Liabilities -1128000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Increase Decrease In Other Operating Capital Net -4157000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Intangible Assets Net Excluding Goodwill 11001000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Inventory Impairment Charge 2129000.0000 USD 4 0001641172-25-009319 Public Utilities Inventory= Inventory Finished Goods;
0001641172-25-009319 20241231 Inventory Noncurrent 12587000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Issuance Of Common Stock As Compensation Expense USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Issuance Of Common Stock As Consideration For Settlement Agreement 175000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Liabilities 123845000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Non Cash Lease Expense -13000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Operating Lease Right Of Use Asset 10990000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Other Assets Noncurrent 270000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent 146000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Payments Of Debt Issuance Costs 1553000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Payments To Acquire Other Productive Assets 1500000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Proceeds From Issuance Initial Public Offering USD 4 us-gaap/2024
0001641172-25-009319 20231231 Proceeds From Short Term Debt Unaffiliated 2000000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Proceeds From Stock Options Exercised 304000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Proceeds From Warrants And Short Term Debt Related Parties 18369000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Repayments Of Short Term Debt Related Party USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Revenue From Contract With Customer Excluding Assessed Tax 5140000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001641172-25-009319 20231231 Shares Paid For Tax Withholding For Share Based Compensation -19130.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Short Term Borrowings 19909000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009319 20231231 Short Term Borrowings 3908000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Bridge Loan;
0001641172-25-009319 20241231 Shortterm Debt Fair Value USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001641172-25-009319 20241231 Shortterm Debt Fair Value 1865000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001641172-25-009319 20231231 Stockholders Equity 19000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stockholders Equity -841791000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value Consideration For Settlement Agreement USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Value Conversion Of Convertible Securities 1700000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Stock Issued During Period Value Of Common Stock In Registered Direct Offering Net Of Offering Expenses 1322000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Stock Issued During Period Value P I P E Offering Net Of Offering Expenses 12680000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value Stock Options Exercised 304000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Stock Issued During Period Value Stock Options Exercised 304000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Cost Of Revenue 8628000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001641172-25-009319 20241231 Accounts And Other Receivables Net Current 13557000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Adjustments Related To Tax Withholding For Share Based Compensation USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Issuance And Modification Of Warrants 3261000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Warrant Issued USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Capital Expenditures Incurred But Not Yet Paid 223000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 814000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Commitments And Contingencies USD 0 us-gaap/2024
0001641172-25-009319 20240229 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class A; Counterparty Name= Yorkville; Equity Components= Standby Equity Purchase Agreement;
0001641172-25-009319 20231231 Common Stock Shares Authorized 730000000.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20231231 Common Stock Shares Issued 100000.0000 shares 0 us-gaap/2024 Credit Facility= Pre Paid Advance Agreement; Line Of Credit Facility= Yorkville;
0001641172-25-009319 20231231 Cost Of Revenue 5738000.0000 USD 4 us-gaap/2024 Product Or Service= License Royalty And Other;
0001641172-25-009319 20241231 Cost Of Revenue 1172000.0000 USD 4 us-gaap/2024 Business Segments= Biobanking;
0001641172-25-009319 20241231 Cost Of Revenue 4924000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001641172-25-009319 20241231 Discounts Arising From Loan Arrangement Related Party USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Earnings Per Share Basic -11.0200 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Employee Benefits And Share Based Compensation 15017000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Fair Value Of Warrant Modification For Professional Services 403000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Impairment Of Intangible Assets Excluding Goodwill USD 4 us-gaap/2024
0001641172-25-009319 20241231 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -57892000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Accounts Payable 9239000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Issuance Of Common Stock Used In Research And Development 1000000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Long Term Debt Noncurrent USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009319 20231231 Modification Of C V Starr Warrants In Connection With Forbearance USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Operating Lease Liability Noncurrent 26177000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Other Nonoperating Income 331000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Payments Related To Tax Withholding For Share Based Compensation 434000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Payments To Acquire Other Productive Assets USD 4 us-gaap/2024
0001641172-25-009319 20231231 Preferred Stock Value USD 0 us-gaap/2024
0001641172-25-009319 20241231 Prepaid Expense And Other Assets Current 857000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20230331 Proceeds From Issuance Of Private Placement 2000000.0000 USD 0 us-gaap/2024 Equity Components= March Two Thousand Twenty Three Private Investment In Public Equity Warrants; Title Of Individual= Dr Hariri; Type Of Arrangement= Securities Purchase Agreement;
0001641172-25-009319 20231231 Proceeds From The Sale Of Common Stock In Atm Offering 136000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Provision For Doubtful Accounts 1233000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Research And Development Expense 30465000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Restricted Cash Noncurrent 9936000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Restricted Cash Noncurrent 9936000.0000 USD 0 us-gaap/2024 Pledging Purpose= Letter Of Credit;
0001641172-25-009319 20231231 Revenue From Contract With Customer Excluding Assessed Tax 22771000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Revenue From Contract With Customer Excluding Assessed Tax 5441000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001641172-25-009319 20241231 Revenue From Contract With Customer Excluding Assessed Tax 54220000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Short Term Borrowings 17223000.0000 USD 0 us-gaap/2024 Line Of Credit Facility= Yorkville;
0001641172-25-009319 20241231 Short Term Borrowings 3876000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009319 20241231 Shortterm Debt Fair Value 2485000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Stockholders Equity 2000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20230531 Stock Issued During Period Shares New Issues 581394.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A; Equity Components= May Two Thousand Twenty Three Private Investment In Public Equity Warrants;
0001641172-25-009319 20231231 Stock Issued During Period Shares New Issues 2141098.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A; Class Of Warrant Or Right= January Two Thousand Twenty Four Pipe Warrants; Subsidiary Sale Of Stock= Private Placement;
0001641172-25-009319 20231231 Stock Issued During Period Shares Of Common Stock In Registered Direct Offering Net Of Offering Expenses 1780220.0000 shares 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value A T M Agreement 136000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Stock Issued During Period Value Consideration For Settlement Agreement 175000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Stock Issued During Period Value Consideration For Settlement Agreement 175000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value Conversion Of Convertible Securities 4598000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Stock Issued During Period Value Conversion Of Convertible Securities USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Issued During Period Value For Debt Extension And Commitment Fee USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Issued During Period Value For Debt Extension And Commitment Fee USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value Of Common Stock In Registered Direct Offering Net Of Offering Expenses 2000.0000 USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value Of Research And Development USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value Share Based Compensation USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Stock Issued During Period Values Short Term Debt Maturity Extension USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Warrant Liability 3264000.0000 USD 0 0001641172-25-009319
0001641172-25-009319 20241231 Weighted Average Number Of Diluted Shares Outstanding 21890518.0000 shares 4 us-gaap/2024
0001641172-25-009319 20241231 Accrued Liabilities And Other Liabilities 19842000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Additional Paid In Capital 908523000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Adjustments Related To Tax Withholding For Share Based Compensation 101000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Adjustments Related To Tax Withholding For Share Based Compensation USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Adjustments Related To Tax Withholding For Share Based Compensation 101000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Adjustments Related To Tax Withholding For Share Based Compensation USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Assumption Of Shortterm Debt Unaffiliated By Related Party USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 -104339000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Cash And Cash Equivalents At Carrying Value 227000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Cash And Cash Equivalents At Carrying Value 738000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20221231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 28802000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Conversion Of Stock Amount Issued1 1700000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Cost Of Revenue USD 4 us-gaap/2024 Business Segments= Cell Therapy;
0001641172-25-009319 20241231 Earnings Per Share Basic -2.6400 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Fair Value Of Warrant Modification For Professional Services USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Goodwill 7347000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20230930 Goodwill Impairment Loss 82714000.0000 USD 1 us-gaap/2024 Business Segments= Cell Therapy;
0001641172-25-009319 20231231 Increase Decrease In Accounts Payable 8497000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Accounts Receivable 3968000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Prepaid Deferred Expense And Other Assets -905000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Issuance Of Common Stock Used In Research And Development USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Issuance Of Rwi Warrants In Connection With Forbearance 1162000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Issuance Of Warrants On Senior Secured Bridge Loan USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Liabilities And Stockholders Equity 143889000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Net Cash Provided By Used In Financing Activities 6701000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Net Cash Provided By Used In Operating Activities -38685000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Net Income Loss -196295000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Non Cash Interest Expense USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Operating Income Loss -192287000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Operating Lease Liability Noncurrent 26548000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Other Assets Noncurrent 337000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent 146000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20240930 Payments To Acquire Other Productive Assets 1500000.0000 USD 0 us-gaap/2024 Asset Acquisition= Sequence Life Science Inc;
0001641172-25-009319 20241231 Preferred Stock Value USD 0 us-gaap/2024
0001641172-25-009319 20231231 Proceeds From Issuance Initial Public Offering 9000000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20230331 Proceeds From Issuance Of Private Placement 2000000.0000 USD 0 us-gaap/2024 Equity Components= March Two Thousand Twenty Three Private Investment In Public Equity Warrants; Subsidiary Sale Of Stock= Private Placement; Title Of Individual= Chairman And Chief Executive Officer;
0001641172-25-009319 20231231 Promissory Notes Receivable 2072000.0000 USD 0 0001641172-25-009319
0001641172-25-009319 20231231 Property Plant And Equipment Net 67828000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Reduction Of Right Of Use Assets And Associated Lease Liability Due To Lease Modification -2083000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Restricted Cash Noncurrent 10239000.0000 USD 0 us-gaap/2024 Pledging Purpose= Letter Of Credit;
0001641172-25-009319 20241231 Revenue From Contract With Customer Excluding Assessed Tax 688000.0000 USD 4 us-gaap/2024 Business Segments= Cell Therapy;
0001641172-25-009319 20221231 Shares Outstanding 14892129.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Shares Outstanding 22546671.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Short Term Borrowings 2108000.0000 USD 0 us-gaap/2024 Title Of Individual= Chairman And Chief Executive Officer;
0001641172-25-009319 20241231 Shortterm Debt Fair Value 1865000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001641172-25-009319 20241231 Stockholders Equity 8837000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Stock Issued During Period Shares Conversion Of Convertible Securities 559481.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Shares New Issues 13296.0000 shares 4 us-gaap/2024 Class Of Stock= Common Stock; Equity Components= At The Market Sales Agreement;
0001641172-25-009319 20241231 Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures 401013.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Shares Share Based Compensation 59176.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Value Conversion Of Convertible Securities USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value New Issues 6000000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Stock Issued During Period Value New Issues USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Stock Issued During Period Value Of Common Stock In Registered Direct Offering Net Of Offering Expenses 1320000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value Of Research And Development USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Stock Issued During Period Value P I P E Offering Net Of Offering Expenses USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Stock Issued During Period Values Short Term Debt Maturity Extension 712000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Stock Repurchased And Retired During Period Shares 191.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Repurchased And Retired During Period Value USD 4 us-gaap/2024
0001641172-25-009319 20241231 Cost Of Revenue 14989000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Fair Value Of Warrant Modification For Professional Service USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -196285000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Accounts Payable Current 23296000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Adjustments Related To Tax Withholding For Share Based Compensation 434000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Issuance And Modification Of Warrants USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability Classified To Equity Classified 2970000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability Classified To Equity Classified 2970000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Warrant Issued 2290000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Warrant Issued 2290000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Warrant Issued USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Asset Acquisition Contingent Consideration Liability Current 650000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20230831 Cash And Cash Equivalents At Carrying Value 3000000.0000 USD 0 us-gaap/2024 Short Term Debt Type= Bridge Loan;
0001641172-25-009319 20241231 Change In Fair Value Of Contingent Stock Consideration USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Common Stock Shares Authorized 730000000.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20241231 Common Stock Shares Issued 22546671.0000 shares 0 us-gaap/2024
0001641172-25-009319 20231231 Common Stock Shares Outstanding 19378192.0000 shares 0 us-gaap/2024
0001641172-25-009319 20241231 Common Stock Shares Outstanding 22546671.0000 shares 0 us-gaap/2024
0001641172-25-009319 20241231 Contract With Customer Liability Noncurrent 2724000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Increase Decrease In Accrued Research Development Software Expense -3834000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Increase Decrease In Contract With Customer Liability 1528000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Increase Decrease In Inventories 865000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Inventories -6284000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Inventory Noncurrent 16657000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Issuance Of Warrants On Senior Secured Bridge Loan 2002000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Liabilities 102929000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Liabilities And Stockholders Equity 132682000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Long Term Debt Noncurrent 35927000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Related Party;
0001641172-25-009319 20241231 Net Cash Provided By Used In Operating Activities -6401000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Net Income Loss USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20241231 Nonoperating Income Expense -19534000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Operating Income Costs And Expenses 215058000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Operating Income Costs And Expenses 92578000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Operating Income Loss -38358000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 146000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Other Nonoperating Income Expenses -9599000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Payments To Acquire Property Plant And Equipment 161000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Proceeds From Convertible Note USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Proceeds From Issuance Of Private Placement 6000000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Provision For Doubtful Accounts 457000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Reclassification Of Warrants From Liability Classified To Equity Classified 2970000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Repayments Of Short Term Debt Unaffiliated 17374000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Research And Development Expense 17386000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Restricted Cash Noncurrent 10239000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Retained Earnings Accumulated Deficit -899683000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Short Term Borrowings 19331000.0000 USD 0 us-gaap/2024 Related Party Transactions By Related Party= Nonrelated Party;
0001641172-25-009319 20241231 Short Term Borrowings 3876000.0000 USD 0 us-gaap/2024 Short Term Debt Type= C E O Promissory Note; Title Of Individual= Chairman And Chief Executive Officer;
0001641172-25-009319 20241231 Shortterm Debt Fair Value USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001641172-25-009319 20221231 Stockholders Equity 844373000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20221231 Stockholders Equity -645496000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Stockholders Equity USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stockholders Equity -5000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Issued During Period Shares Conversion Of Convertible Securities 478881.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20230331 Stock Issued During Period Shares New Issues 923076.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20230331 Stock Issued During Period Shares New Issues 938183.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A; Equity Components= March Two Thousand Twenty Three Private Investment In Public Equity Warrants;
0001641172-25-009319 20231231 Stock Issued During Period Shares Of Research And Development 169492.0000 shares 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Shares P I P E Offering Net Of Offering Expenses 1519579.0000 shares 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Shares Stock Options Exercised 108637.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Shares Stock Options Exercised 20744.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value A T M Agreement 136000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value Conversion Of Convertible Securities -155000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Stock Issued During Period Value Of Common Stock In Registered Direct Offering Net Of Offering Expenses USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Issued During Period Value Share Based Compensation USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Values Short Term Debt Maturity Extension 712000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Values Short Term Debt Maturity Extension USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value Stock Options Exercised USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Repurchased And Retired During Period Value 17000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Repurchased And Retired During Period Value USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20230731 Warrant Liability 511000.0000 USD 0 0001641172-25-009319
0001641172-25-009319 20231231 Weighted Average Number Of Shares Outstanding Basic 17813044.0000 shares 4 us-gaap/2024
0001641172-25-009319 20231231 Accrued Research And Development Software 3500000.0000 USD 0 0001641172-25-009319
0001641172-25-009319 20231231 Adjustments Related To Tax Withholding For Share Based Compensation USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Adjustments Related To Tax Withholding For Share Based Compensation USD 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Issuance And Modification Of Warrants USD 4 0001641172-25-009319 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability Classified To Equity Classified USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Adjustments To Additional Paid In Capital Warrant Issued USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Assets 143889000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Assets 132682000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Assets Current 19793000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20230630 Cash And Cash Equivalents At Carrying Value 3000000.0000 USD 0 us-gaap/2024 Debt Instrument= Loan Agreement; Line Of Credit Facility= C V Starr Co Inc;
0001641172-25-009319 20240229 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20231231 Common Stock Shares Authorized 730000000.0000 shares 0 us-gaap/2024
0001641172-25-009319 20241231 Common Stock Shares Authorized 730000000.0000 shares 0 us-gaap/2024
0001641172-25-009319 20231231 Common Stock Shares Issued 19378192.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001641172-25-009319 20231231 Contingent Consideration Accrued In Connection With Rebound Asset Acquisition USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Cost Of Revenue 8893000.0000 USD 4 us-gaap/2024 Product Or Service= License Royalty And Other;
0001641172-25-009319 20241231 Cost Of Revenue 1172000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001641172-25-009319 20231231 Depreciation Depletion And Amortization 9324000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Discounts Arising From Loan Arrangement Related Party 2151000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Fair Value Of Warrant Modification For Professional Service USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Income Tax Expense Benefit 10000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Increase Decrease In Operating Lease Liability 275000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Operating Lease Liability 371000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Increase Decrease In Other Operating Capital Net -300000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Interest Accrued On Senior Secured Loans Within Long Term Debt Related Parties -1770000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Inventory Acquired In Connection With Rebound Asset Acquisition USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Inventory Net 5409000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Liabilities Current 53680000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Modification Of C V Starr Warrants In Connection With Forbearance 51000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Net Cash Provided By Used In Financing Activities 24094000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20231231 Net Cash Provided By Used In Investing Activities -4048000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Net Cash Provided By Used In Investing Activities 514000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Net Income Loss -57892000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Non Cash Interest Expense 4144000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Non Cash Lease Expense 160000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Other Liabilities Noncurrent 294000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20241231 Payment Of Sepa Commitment Fee 25000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Payments Of Debt Issuance Costs USD 4 us-gaap/2024
0001641172-25-009319 20231231 Preferred Stock Shares Authorized 10000000.0000 shares 0 us-gaap/2024
0001641172-25-009319 20241231 Preferred Stock Shares Authorized 10000000.0000 shares 0 us-gaap/2024
0001641172-25-009319 20231231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001641172-25-009319 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001641172-25-009319 20231231 Prepaid Expense And Other Assets Current 1695000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Proceeds From Issuance Of Private Placement 12750000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Proceeds From Stock Options Exercised 58000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Proceeds From The Sale Of Common Stock In Atm Offering USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Property Plant And Equipment Net 61600000.0000 USD 0 us-gaap/2024
0001641172-25-009319 20231231 Revenue From Contract With Customer Excluding Assessed Tax USD 4 us-gaap/2024 Business Segments= Cell Therapy;
0001641172-25-009319 20241231 Revenue From Contract With Customer Excluding Assessed Tax 35336000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001641172-25-009319 20241231 Shares Paid For Tax Withholding For Share Based Compensation -109790.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20240731 Short Term Borrowings 13700000.0000 USD 0 us-gaap/2024 Credit Facility= Forbearance Agreement; Equity Components= Warrant; Short Term Debt Type= Bridge Loan;
0001641172-25-009319 20241231 Short Term Borrowings 2485000.0000 USD 0 us-gaap/2024 Line Of Credit Facility= Yorkville;
0001641172-25-009319 20241231 Stockholders Equity -899683000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20230331 Stock Issued During Period Shares New Issues 169492.0000 shares 0 us-gaap/2024 Equity Components= Common Stock; Type Of Arrangement= Pulthera L L C Binding Term Sheet;
0001641172-25-009319 20230731 Stock Issued During Period Shares New Issues 857142.0000 shares 0 us-gaap/2024
0001641172-25-009319 20241231 Stock Issued During Period Shares New Issues 2141098.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures 83759.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001641172-25-009319 20241231 Stock Issued During Period Value For Debt Extension And Commitment Fee 317000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20241231 Stock Issued During Period Value For Debt Extension And Commitment Fee 317000.0000 USD 4 0001641172-25-009319 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value New Issues 1000000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock; Type Of Arrangement= Pulthera L L C Binding Term Sheet;
0001641172-25-009319 20241231 Stock Issued During Period Value New Issues 6000000.0000 USD 4 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001641172-25-009319 20231231 Stock Issued During Period Value Of Common Stock In Registered Direct Offering Net Of Offering Expenses USD 4 0001641172-25-009319 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Stock Issued During Period Value P I P E Offering Net Of Offering Expenses 12681000.0000 USD 4 0001641172-25-009319
0001641172-25-009319 20231231 Stock Issued During Period Value P I P E Offering Net Of Offering Expenses 1000.0000 USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20241231 Stock Issued During Period Value Share Based Compensation USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001641172-25-009319 20231231 Stock Issued During Period Values Short Term Debt Maturity Extension USD 4 0001641172-25-009319 Equity Components= Common Stock;
0001641172-25-009319 20231231 Stock Issued During Period Value Stock Options Exercised USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Issued During Period Value Stock Options Exercised 58000.0000 USD 4 us-gaap/2024
0001641172-25-009319 20241231 Stock Issued During Period Value Stock Options Exercised USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20241231 Stock Repurchased And Retired During Period Value USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001641172-25-009319 20231231 Warrant Liability 4359000.0000 USD 0 0001641172-25-009319
0001641172-25-009319 20231231 Weighted Average Number Of Diluted Shares Outstanding 17813044.0000 shares 4 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Other Nonoperating Income us-gaap/2024 0 0 monetary D C Other Nonoperating Income Amount of income related to nonoperating activities, classified as other.
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Stock Issued During Period Value Stock Options Exercised us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Stock Options Exercised Value of stock issued as a result of the exercise of stock options.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Excluding Assessed Tax Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Adjustments To Additional Paid In Capital Warrant Issued us-gaap/2024 0 0 monetary D C Adjustments to Additional Paid in Capital, Warrant Issued Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Issuance Of Warrants On Senior Secured Bridge Loan 0001641172-25-009319 1 0 monetary D D Issuance of warrants on senior secured bridge loan Issuance of warrants on senior secured bridge loan.
Stock Issued During Period Value P I P E Offering Net Of Offering Expenses 0001641172-25-009319 1 0 monetary D C Issuance of common stock in PIPE Offering, net of offering expenses Stock issued during period value PIPE offering net of offering expenses.
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Assumption Of Shortterm Debt Unaffiliated By Related Party 0001641172-25-009319 1 0 monetary D D Assumption of short-term debt - unaffiliated by related party Assumption of short-term debt - unaffiliated by related party.
Allowance For Doubtful Accounts Receivable Current us-gaap/2024 0 0 monetary I C Accounts Receivable, Allowance for Credit Loss, Current Amount of allowance for credit loss on accounts receivable, classified as current.
Asset Acquisition Contingent Consideration Liability Current us-gaap/2024 0 0 monetary I C Asset Acquisition, Contingent Consideration, Liability, Current Amount of liability recognized from contingent consideration in asset acquisition, classified as current.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Increase Decrease In Contract With Customer Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Contract with Customer, Liability Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Proceeds From Issuance Of Private Placement us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Private Placement The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
Proceeds From Stock Options Exercised us-gaap/2024 0 0 monetary D D Proceeds from Stock Options Exercised Amount of cash inflow from exercise of option under share-based payment arrangement.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Inventory Impairment Charge 0001641172-25-009319 1 0 monetary D D Inventory impairment Inventory Impairment Charge.
Issuance Of Common Stock As Compensation Expense 0001641172-25-009319 1 0 monetary D D IssuanceOfCommonStockAsCompensationExpense Issuance of common stock as compensation expense.
Proceeds From The Sale Of Common Stock In Atm Offering 0001641172-25-009319 1 0 monetary D D Proceeds from the sale of common stock in ATM offering Proceeds from the sale of common stock in Atm offering.
Additional Paid In Capital us-gaap/2024 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Adjustments Related To Tax Withholding For Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Payments Of Debt Issuance Costs us-gaap/2024 0 0 monetary D C Payments of Debt Issuance Costs The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
Stock Issued During Period Value Conversion Of Convertible Securities us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Conversion of Convertible Securities The gross value of stock issued during the period upon the conversion of convertible securities.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.
Stock Issued During Period Value Share Based Compensation us-gaap/2024 0 0 monetary D C Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
Accrued Liabilities And Other Liabilities us-gaap/2024 0 0 monetary I C Accrued Liabilities and Other Liabilities Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.
Acquired In Process Research And Development 0001641172-25-009319 1 0 monetary D D Acquired in-process research and development Acquired In-process Research And Development.
Discounts Arising From Loan Arrangement Related Party 0001641172-25-009319 1 0 monetary D D Discounts arising from RWI loan arrangement - related party Discounts arising from loan arrangement related party.
P I P E Related Costs Included In Accrued Expenses 0001641172-25-009319 1 0 monetary D D PIPE related costs included in accrued expenses PIPE related costs included in accrued expenses.
Repayments Of Short Term Debt Unaffiliated 0001641172-25-009319 1 0 monetary D C RepaymentsOfShortTermDebtUnaffiliated Repayments of short term debt unaffiliated.
Stock Issued During Period Shares Short Term Debt Maturity Extension 0001641172-25-009319 1 0 shares D Common stock issued pursuant to short-term debt maturity extension, shares Stock issued during period shares short term debt maturity extension.
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Impairment Of Intangible Assets Excluding Goodwill us-gaap/2024 0 0 monetary D D Impairment of Intangible Assets (Excluding Goodwill) The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Conversion of Convertible Securities Number of shares issued during the period as a result of the conversion of convertible securities.
Stock Repurchased And Retired During Period Shares us-gaap/2024 0 0 shares D Stock Repurchased and Retired During Period, Shares Number of shares that have been repurchased and retired during the period.
Provision For Inventory Obsolescence 0001641172-25-009319 1 0 monetary D D Provision for inventory obsolescence Provision for Inventory Obsolescence.
Reclassification Of Warrants From Liability Classified To Equity Classified 0001641172-25-009319 1 0 monetary D C ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified Reclassification of warrants from liability classified to equity classified.
Stock Issued During Period Shares Of Research And Development 0001641172-25-009319 1 0 shares D Issuance of common stock for stem-cells to be used in research and development, shares Stock issued during period shares of research and development.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Cost Of Revenue us-gaap/2024 0 0 monetary D D Cost of Revenue The aggregate cost of goods produced and sold and services rendered during the reporting period.
Depreciation Depletion And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Goodwill Impairment Loss us-gaap/2024 0 0 monetary D D Goodwill, Impairment Loss Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.
Accrued Research And Development Software 0001641172-25-009319 1 0 monetary I C Accrued R&D software Accrued research and development software.
Increase Decrease In Other Accounts Payable And Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Other Accounts Payable and Accrued Liabilities The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.
Increase Decrease In Other Operating Capital Net us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Operating Assets and Liabilities, Net Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.
Issuance Of Rwi Warrants In Connection With Forbearance 0001641172-25-009319 1 0 monetary D C Issuance of RWI warrants in connection with forbearance Issuance of rwi warrants in connection with for bearance.
Non Cash Interest Expense 0001641172-25-009319 1 0 monetary D D Non cash interest expense Non cash interest expense.
Operating Income Costs And Expenses 0001641172-25-009319 1 0 monetary D D OperatingIncomeCostsAndExpenses Operating income costs and expenses.
Stock Issued During Period Shares For Debt Extension And Commitment Fee 0001641172-25-009319 1 0 shares D Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, shares Stock issued during period shares for debt extension and commitment fee.
Stock Issued During Period Value For Debt Extension And Commitment Fee 0001641172-25-009319 1 0 monetary D D Issuance of common stock to Yorkville for debt extension and SEPA commitment fee Stock issued during period value for debt extension and commitment fee.
Adjustments To Additional Paid In Capital Issuance And Modification Of Warrants 0001641172-25-009319 1 0 monetary D C Issuance and modification of warrants to RWI and C.V. Starr Adjustments to additional paid in capital issuance and modification of warrants.
Accounts And Other Receivables Net Current us-gaap/2024 0 0 monetary I D Accounts and Other Receivables, Net, Current Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Nonoperating Income (Expense) The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Other Nonoperating Expense us-gaap/2024 0 0 monetary D D Other Nonoperating Expense Amount of expense related to nonoperating activities, classified as other.
Preferred Stock Value us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Stock Repurchased And Retired During Period Value us-gaap/2024 0 0 monetary D D Stock Repurchased and Retired During Period, Value Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).
Issuance Of Common Stock Used In Research And Development 0001641172-25-009319 1 0 monetary D D IssuanceOfCommonStockUsedInResearchAndDevelopment Issuance of common stock used in research and development.
Modification Of C V Starr Warrants In Connection With Forbearance 0001641172-25-009319 1 0 monetary D C Modification of C.V. Starr warrants in connection with forbearance Modification of CV starr warrants in connection with forbearance.
Proceeds From Warrants And Short Term Debt Related Parties 0001641172-25-009319 1 0 monetary D D Proceeds from warrants and short-term debt - related parties Proceeds from warrants and short term debt related parties.
Reduction Of Right Of Use Assets And Associated Lease Liability Due To Lease Modification 0001641172-25-009319 1 0 monetary D C Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification Reduction of right of use assets and associated lease liability due to lease modification.
Stock Issued During Period Shares Of Common Stock In Registered Direct Offering Net Of Offering Expenses 0001641172-25-009319 1 0 shares D Issuance of common stock in Registered Direct Offering, net of offering expenses, shares Stock issued during period shares of common stock in registered direct offering net of offering expenses.
Stock Issued During Period Value Of Common Stock In Registered Direct Offering Net Of Offering Expenses 0001641172-25-009319 1 0 monetary D C Issuance of common stock in Registered Direct Offering, net of offering expenses Stock issued during period value of common stock in registered direct offering net of offering expenses.
Stock Issued During Period Value Of Research And Development 0001641172-25-009319 1 0 monetary D C Issuance of common stock for stem-cells to be used in research and development Stock issued during period value of research and development.
Stock Issued During Period Values Short Term Debt Maturity Extension 0001641172-25-009319 1 0 monetary D C Common stock issued pursuant to short-term debt maturity extension Stock issued during period value short term debt maturity extension.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 us-gaap/2024 0 0 monetary D D Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
Goodwill us-gaap/2024 0 0 monetary I D Goodwill Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Intangible Assets Net Excluding Goodwill us-gaap/2024 0 0 monetary I D Intangible Assets, Net (Excluding Goodwill) Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Prepaid Expense And Other Assets Current us-gaap/2024 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Proceeds From Issuance Initial Public Offering us-gaap/2024 0 0 monetary D D Proceeds from Issuance Initial Public Offering The cash inflow associated with the amount received from entity's first offering of stock to the public.
Restricted Cash Noncurrent us-gaap/2024 0 0 monetary I D Restricted Cash, Noncurrent Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Short Term Borrowings us-gaap/2024 0 0 monetary I C Short-Term Debt Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
Change In Fair Value Of Contingent Stock Consideration 0001641172-25-009319 1 0 monetary D D Change in fair value of contingent stock consideration Change in fair value of contingent stock consideration.
Fair Value Of Warrant Modification For Professional Services 0001641172-25-009319 1 0 monetary D D FairValueOfWarrantModificationForProfessionalServices Fair Value Of Warrant Modification For Professional Services.
Payment Of Sepa Commitment Fee 0001641172-25-009319 1 0 monetary D C PaymentOfSepaCommitmentFee Payment of sepa commitment fee.
Proceeds From Convertible Note 0001641172-25-009319 1 0 monetary D C ProceedsFromConvertibleNote Proceeds from convertible note.
Stock Issued During Period Value A T M Agreement 0001641172-25-009319 1 0 monetary D C Issuance of common stock under ATM Agreement Stock issued during period value for ATM agreement.
Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 0 0 monetary D C Capital Expenditures Incurred but Not yet Paid Future cash outflow to pay for purchases of fixed assets that have occurred.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Inventory Noncurrent us-gaap/2024 0 0 monetary I D Inventory, Noncurrent Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Amount after tax of other comprehensive income (loss) attributable to parent entity.
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Stock Issued During Period Shares New Issues us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, New Issues Number of new stock issued during the period.
Change In Fair Value Of Debt 0001641172-25-009319 1 0 monetary D D Change in fair value of debt Change in fair value of debt.
Fair Value Of Warrant Modification For Professional Service 0001641172-25-009319 1 0 monetary D C Fair value of warrant modification for professional services Fair Value Of Warrant Modification For Professional Services.
Increase Decrease In Accrued Research Development Software Expense 0001641172-25-009319 1 0 monetary D D IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense Increase decrease in accrued research development software expense.
Proceeds From Short Term Debt Unaffiliated 0001641172-25-009319 1 0 monetary D D Proceeds from issuance of short-term debt - unaffiliated Proceeds from short term debt unaffiliated
Stock Issued During Period Shares A T M Agreement 0001641172-25-009319 1 0 shares D Issuance of common stock under ATM Agreement, shares Stock issued during period shares for ATM agreement.
Amortization Of Intangible Assets us-gaap/2024 0 0 monetary D D Amortization of Intangible Assets The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Asset Acquisition Contingent Consideration Liability us-gaap/2024 0 0 monetary I C Asset Acquisition, Contingent Consideration, Liability Amount of liability recognized from contingent consideration in asset acquisition.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Contract With Customer Liability Noncurrent us-gaap/2024 0 0 monetary I C Contract with Customer, Liability, Noncurrent Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
Gains Losses On Extinguishment Of Debt us-gaap/2024 0 0 monetary D C Gain (Loss) on Extinguishment of Debt Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
Deferred Income Tax Liabilities Net us-gaap/2024 0 0 monetary I C Deferred Income Tax Liabilities, Net Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Employee Benefits And Share Based Compensation us-gaap/2024 0 0 monetary D D Employee Benefits and Share-Based Compensation Amount of expense for employee benefit and equity-based compensation.
Fair Value Adjustment Of Warrants us-gaap/2024 0 0 monetary D D Fair Value Adjustment of Warrants Amount of expense (income) related to adjustment to fair value of warrant liability.
Interest Accrued On Senior Secured Loans Within Long Term Debt Related Parties 0001641172-25-009319 1 0 monetary D D Interest accrued on senior secured loans within long-term debt - related parties Interest accrued on senior secured loans within long term debt related parties.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Increase Decrease In Operating Lease Liability us-gaap/2024 0 0 monetary D D Increase (Decrease) in Operating Lease Liability Amount of increase (decrease) in obligation for operating lease.
Interest Paid Net us-gaap/2024 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activities Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent Amount, before tax, after reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.
Payments Related To Tax Withholding For Share Based Compensation us-gaap/2024 0 0 monetary D C Payment, Tax Withholding, Share-Based Payment Arrangement Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.
Payments To Acquire Other Productive Assets us-gaap/2024 0 0 monetary D C Payments to Acquire Other Productive Assets Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Shares Outstanding us-gaap/2024 0 0 shares I Shares, Outstanding Number of shares issued which are neither cancelled nor held in the treasury.
Shares Paid For Tax Withholding For Share Based Compensation us-gaap/2024 0 0 shares D Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.
Promissory Notes Receivable 0001641172-25-009319 1 0 monetary I D Notes receivable Promissory notes receivable.
Stock Issued During Period Shares P I P E Offering Net Of Offering Expenses 0001641172-25-009319 1 0 shares D Issuance of common stock in PIPE Offering, net of offering expenses, shares Stock issued during period shares PIPE offering net of offering expenses.
Contract With Customer Liability Current us-gaap/2024 0 0 monetary I C Contract with Customer, Liability, Current Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Shortterm Debt Fair Value us-gaap/2024 0 0 monetary I C Short-Term Debt, Fair Value This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.
Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 0 0 shares D Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Number of share options (or share units) exercised during the current period.
Stock Issued During Period Value New Issues us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, New Issues Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
Issuance Of Common Stock Relating To Debt Extension And Commitment Fee 0001641172-25-009319 1 0 monetary D D IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee Issuance of common stock relating to debt extension and commitment fee.
Non Cash Lease Expense 0001641172-25-009319 1 0 monetary D D Non cash lease expense Non cash lease expense.
Repayments Of Short Term Debt Related Party 0001641172-25-009319 1 0 monetary D C RepaymentsOfShortTermDebtRelatedParty Repayments of short term debt related party.
Stock Issued During Period Value Consideration For Settlement Agreement 0001641172-25-009319 1 0 monetary D D Issuance of common stock to Palantir as consideration for settlement agreement Stock issued during period value for consideration for settlement agreement.
Conversion Of Stock Amount Issued1 us-gaap/2024 0 0 monetary D C Conversion of Stock, Amount Issued The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
Long Term Debt Noncurrent us-gaap/2024 0 0 monetary I C Long-Term Debt, Excluding Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Payments To Acquire In Process Research And Development us-gaap/2024 0 0 monetary D C Payments to Acquire in Process Research and Development The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.
Provision For Doubtful Accounts us-gaap/2024 0 0 monetary D D Accounts Receivable, Credit Loss Expense (Reversal) Amount of expense (reversal of expense) for expected credit loss on accounts receivable.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Stock Issued During Period Shares Share Based Compensation us-gaap/2024 0 0 shares D Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability Classified To Equity Classified 0001641172-25-009319 1 0 monetary D C Reclassification of warrants from liability classified to equity classified Adjustments to additional paid in capital reclassification of warrants from liability classified to equity classified.
Contingent Consideration Accrued In Connection With Rebound Asset Acquisition 0001641172-25-009319 1 0 monetary D D Contingent consideration accrued in connection with Rebound asset acquisition Contingent consideration accrued in connection with Rebound asset acquisition.
Inventory Acquired In Connection With Rebound Asset Acquisition 0001641172-25-009319 1 0 monetary D D Inventory acquired in connection with Rebound asset acquisition Inventory acquired in connection with Rebound asset acquisition.
Issuance Of Common Stock As Consideration For Settlement Agreement 0001641172-25-009319 1 0 monetary D D IssuanceOfCommonStockAsConsiderationForSettlementAgreement Issuance of common stock as consideration for settlement agreement.
Other Nonoperating Income Expenses 0001641172-25-009319 1 0 monetary D C Other expense, net Other nonoperating income expenses.
Stock Issued During Period Shares Consideration For Settlement Agreement 0001641172-25-009319 1 0 shares D Issuance of common stock to Palantir as consideration for settlement agreement, shares Stock issued during period shares for consideration for settlement agreement.
Warrant Liability 0001641172-25-009319 1 0 monetary I C Warrant liabilities Warrant liability.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001641172-25-009319 2 9 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0001641172-25-009319 2 10 BS 0 H Accounts And Other Receivables Net Current us-gaap/2024 Accounts receivable, net of allowance of $6,294 and $5,837 as of December 31, 2024 and 2023, respectively 0
0001641172-25-009319 2 11 BS 0 H Promissory Notes Receivable 0001641172-25-009319 Notes receivable 0
0001641172-25-009319 2 12 BS 0 H Inventory Net us-gaap/2024 Inventory 0
0001641172-25-009319 2 13 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other current assets 0
0001641172-25-009319 2 14 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0001641172-25-009319 2 15 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property and equipment, net 0
0001641172-25-009319 2 16 BS 0 H Goodwill us-gaap/2024 Goodwill 0
0001641172-25-009319 2 17 BS 0 H Intangible Assets Net Excluding Goodwill us-gaap/2024 Intangible assets, net 0
0001641172-25-009319 2 18 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Right-of-use assets - operating leases 0
0001641172-25-009319 2 19 BS 0 H Restricted Cash Noncurrent us-gaap/2024 Restricted cash 0
0001641172-25-009319 2 20 BS 0 H Inventory Noncurrent us-gaap/2024 Inventory, net of current portion 0
0001641172-25-009319 2 21 BS 0 H Other Assets Noncurrent us-gaap/2024 Other long-term assets 0
0001641172-25-009319 2 22 BS 0 H Assets us-gaap/2024 Total assets 0
0001641172-25-009319 2 25 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001641172-25-009319 2 26 BS 0 H Accrued Liabilities And Other Liabilities us-gaap/2024 Accrued expenses and other current liabilities 0
0001641172-25-009319 2 27 BS 0 H Accrued Research And Development Software 0001641172-25-009319 Accrued R&D software 0
0001641172-25-009319 2 28 BS 0 H Asset Acquisition Contingent Consideration Liability Current us-gaap/2024 Acquisition-related contingent consideration 0
0001641172-25-009319 2 29 BS 0 H Short Term Borrowings us-gaap/2024 Short-term debt 0
0001641172-25-009319 2 30 BS 0 H Contract With Customer Liability Current us-gaap/2024 Deferred revenue 0
0001641172-25-009319 2 31 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0001641172-25-009319 2 32 BS 0 H Contract With Customer Liability Noncurrent us-gaap/2024 Deferred revenue, net of current portion 0
0001641172-25-009319 2 33 BS 0 H Asset Acquisition Contingent Consideration Liability us-gaap/2024 Acquisition-related contingent consideration, net of current portion 0
0001641172-25-009319 2 34 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Long-term debt - related parties 0
0001641172-25-009319 2 35 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Long-term lease liabilities 0
0001641172-25-009319 2 36 BS 0 H Warrant Liability 0001641172-25-009319 Warrant liabilities 0
0001641172-25-009319 2 37 BS 0 H Deferred Income Tax Liabilities Net us-gaap/2024 Deferred income tax liabilities 0
0001641172-25-009319 2 38 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other liabilities 0
0001641172-25-009319 2 39 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0001641172-25-009319 2 40 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and Contingencies (Note 12) 0
0001641172-25-009319 2 42 BS 0 H Preferred Stock Value us-gaap/2024 Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding as of December 31, 2024 and 2023 0
0001641172-25-009319 2 43 BS 0 H Common Stock Value us-gaap/2024 Common stock, $0.0001 par value, 730,000,000 shares authorized, 22,546,671 and 19,378,192 issued and outstanding as of December 31, 2024 and 2023, respectively 0
0001641172-25-009319 2 44 BS 0 H Additional Paid In Capital us-gaap/2024 Additional paid-in capital 0
0001641172-25-009319 2 45 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0001641172-25-009319 2 46 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive loss 0
0001641172-25-009319 2 47 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders equity 0
0001641172-25-009319 2 48 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders equity 0
0001641172-25-009319 3 1 BS 1 H Allowance For Doubtful Accounts Receivable Current us-gaap/2024 Accounts receivable, allowance 0
0001641172-25-009319 3 2 BS 1 H Shortterm Debt Fair Value us-gaap/2024 Short-term debt, fair value 0
0001641172-25-009319 3 3 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock par value 0
0001641172-25-009319 3 4 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized 0
0001641172-25-009319 3 5 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued 0
0001641172-25-009319 3 6 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding 0
0001641172-25-009319 3 7 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value 0
0001641172-25-009319 3 8 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized 0
0001641172-25-009319 3 9 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued 0
0001641172-25-009319 3 10 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding 0
0001641172-25-009319 4 9 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Total net revenues 0
0001641172-25-009319 4 12 IS 0 H Cost Of Revenue us-gaap/2024 Cost of revenues 0
0001641172-25-009319 4 13 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0001641172-25-009319 4 14 IS 0 H Selling General And Administrative Expense us-gaap/2024 Selling, general and administrative 0
0001641172-25-009319 4 15 IS 0 H Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 us-gaap/2024 Change in fair value of contingent consideration liability 0
0001641172-25-009319 4 16 IS 0 H Goodwill Impairment Loss us-gaap/2024 Goodwill impairment 0
0001641172-25-009319 4 17 IS 0 H Impairment Of Intangible Assets Excluding Goodwill us-gaap/2024 IPR&D impairment 0
0001641172-25-009319 4 18 IS 0 H Amortization Of Intangible Assets us-gaap/2024 Amortization of acquired intangible assets 0
0001641172-25-009319 4 19 IS 0 H Operating Income Costs And Expenses 0001641172-25-009319 Total operating expenses 0
0001641172-25-009319 4 20 IS 0 H Operating Income Loss us-gaap/2024 Loss from operations 0
0001641172-25-009319 4 22 IS 0 H Other Nonoperating Income us-gaap/2024 Interest income 0
0001641172-25-009319 4 23 IS 0 H Other Nonoperating Expense us-gaap/2024 Interest expense 1
0001641172-25-009319 4 24 IS 0 H Fair Value Adjustment Of Warrants us-gaap/2024 Change in fair value of warrant liabilities 1
0001641172-25-009319 4 25 IS 0 H Change In Fair Value Of Debt 0001641172-25-009319 Change in fair value of debt 1
0001641172-25-009319 4 26 IS 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 Loss on debt extinguishment 0
0001641172-25-009319 4 27 IS 0 H Other Nonoperating Income Expenses 0001641172-25-009319 Other expense, net 0
0001641172-25-009319 4 28 IS 0 H Nonoperating Income Expense us-gaap/2024 Total other expense 0
0001641172-25-009319 4 29 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Loss before income taxes 0
0001641172-25-009319 4 30 IS 0 H Income Tax Expense Benefit us-gaap/2024 Income tax expense 0
0001641172-25-009319 4 31 IS 0 H Net Income Loss us-gaap/2024 Net loss 0
0001641172-25-009319 4 32 IS 0 H Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent us-gaap/2024 Change in fair value of debt due to change in credit risk, net of tax 0
0001641172-25-009319 4 33 IS 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 Other comprehensive (loss) income 0
0001641172-25-009319 4 34 IS 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive loss 0
0001641172-25-009319 4 35 IS 0 H Earnings Per Share Basic us-gaap/2024 Net loss per share - basic 0
0001641172-25-009319 4 36 IS 0 H Earnings Per Share Diluted us-gaap/2024 Net loss per share - diluted 0
0001641172-25-009319 4 37 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Weighted average shares outstanding - basic 0
0001641172-25-009319 4 38 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Weighted average shares outstanding - diluted 0
0001641172-25-009319 5 9 EQ 0 H Stockholders Equity us-gaap/2024 Balances 0
0001641172-25-009319 5 10 EQ 0 H Shares Outstanding us-gaap/2024 Balances, shares 0
0001641172-25-009319 5 11 EQ 0 H Stock Issued During Period Value Of Common Stock In Registered Direct Offering Net Of Offering Expenses 0001641172-25-009319 Issuance of common stock in Registered Direct Offering, net of offering expenses 0
0001641172-25-009319 5 12 EQ 0 H Stock Issued During Period Shares Of Common Stock In Registered Direct Offering Net Of Offering Expenses 0001641172-25-009319 Issuance of common stock in Registered Direct Offering, net of offering expenses, shares 0
0001641172-25-009319 5 13 EQ 0 H Stock Issued During Period Values Short Term Debt Maturity Extension 0001641172-25-009319 Common stock issued pursuant to short-term debt maturity extension 0
0001641172-25-009319 5 14 EQ 0 H Stock Issued During Period Shares Short Term Debt Maturity Extension 0001641172-25-009319 Common stock issued pursuant to short-term debt maturity extension, shares 0
0001641172-25-009319 5 15 EQ 0 H Stock Issued During Period Value Stock Options Exercised us-gaap/2024 Exercise of stock options 0
0001641172-25-009319 5 16 EQ 0 H Stock Issued During Period Shares Stock Options Exercised us-gaap/2024 Exercise of stock options, shares 0
0001641172-25-009319 5 17 EQ 0 H Fair Value Of Warrant Modification For Professional Service 0001641172-25-009319 Fair value of warrant modification for professional services 0
0001641172-25-009319 5 18 EQ 0 H Stock Issued During Period Value Of Research And Development 0001641172-25-009319 Issuance of common stock for stem-cells to be used in research and development 0
0001641172-25-009319 5 19 EQ 0 H Stock Issued During Period Shares Of Research And Development 0001641172-25-009319 Issuance of common stock for stem-cells to be used in research and development, shares 0
0001641172-25-009319 5 20 EQ 0 H Adjustments To Additional Paid In Capital Warrant Issued us-gaap/2024 Issuance of warrants to RWI and C.V. Starr 0
0001641172-25-009319 5 21 EQ 0 H Stock Issued During Period Value Conversion Of Convertible Securities us-gaap/2024 Common stock issued pursuant to short-term debt conversion 0
0001641172-25-009319 5 22 EQ 0 H Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2024 Common stock issued pursuant to short-term debt conversion, shares 0
0001641172-25-009319 5 23 EQ 0 H Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures us-gaap/2024 Vesting of restricted stock units 0
0001641172-25-009319 5 24 EQ 0 H Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures us-gaap/2024 Vesting of restricted stock units, shares 0
0001641172-25-009319 5 25 EQ 0 H Adjustments Related To Tax Withholding For Share Based Compensation us-gaap/2024 Tax withholding on vesting of restricted stock units 1
0001641172-25-009319 5 26 EQ 0 H Shares Paid For Tax Withholding For Share Based Compensation us-gaap/2024 Tax withholding on vesting of restricted stock units, shares 0
0001641172-25-009319 5 27 EQ 0 H Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition us-gaap/2024 Stock-based compensation expense 0
0001641172-25-009319 5 28 EQ 0 H Stock Issued During Period Value P I P E Offering Net Of Offering Expenses 0001641172-25-009319 Issuance of common stock in PIPE Offering, net of offering expenses 0
0001641172-25-009319 5 29 EQ 0 H Stock Issued During Period Shares P I P E Offering Net Of Offering Expenses 0001641172-25-009319 Issuance of common stock in PIPE Offering, net of offering expenses, shares 0
0001641172-25-009319 5 30 EQ 0 H Stock Issued During Period Value A T M Agreement 0001641172-25-009319 Issuance of common stock under ATM Agreement 0
0001641172-25-009319 5 31 EQ 0 H Stock Issued During Period Shares A T M Agreement 0001641172-25-009319 Issuance of common stock under ATM Agreement, shares 0
0001641172-25-009319 5 32 EQ 0 H Other Comprehensive Income Loss Financial Liability Fair Value Option Before Tax After Reclassification Adjustment Attributable To Parent us-gaap/2024 Change in fair value of debt due to change in credit risk, net of tax 0
0001641172-25-009319 5 33 EQ 0 H Net Income Loss us-gaap/2024 Net loss 0
0001641172-25-009319 5 34 EQ 0 H Stock Issued During Period Value New Issues us-gaap/2024 Issuance of common stock and warrants in PIPE Offering, net of offering expenses 0
0001641172-25-009319 5 35 EQ 0 H Stock Issued During Period Shares New Issues us-gaap/2024 Issuance of common stock and warrants in PIPE Offering, net of offering expenses, shares 0
0001641172-25-009319 5 36 EQ 0 H Stock Issued During Period Value For Debt Extension And Commitment Fee 0001641172-25-009319 Issuance of common stock to Yorkville for debt extension and SEPA commitment fee 0
0001641172-25-009319 5 37 EQ 0 H Stock Issued During Period Shares For Debt Extension And Commitment Fee 0001641172-25-009319 Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, shares 0
0001641172-25-009319 5 38 EQ 0 H Adjustments To Additional Paid In Capital Issuance And Modification Of Warrants 0001641172-25-009319 Issuance and modification of warrants to RWI and C.V. Starr 0
0001641172-25-009319 5 39 EQ 0 H Stock Repurchased And Retired During Period Value us-gaap/2024 Retirement of shares in connection with reverse stock split 1
0001641172-25-009319 5 40 EQ 0 H Stock Repurchased And Retired During Period Shares us-gaap/2024 Retirement of shares in connection with reverse stock split, shares 1
0001641172-25-009319 5 41 EQ 0 H Stock Issued During Period Value Consideration For Settlement Agreement 0001641172-25-009319 Issuance of common stock to Palantir as consideration for settlement agreement 0
0001641172-25-009319 5 42 EQ 0 H Stock Issued During Period Shares Consideration For Settlement Agreement 0001641172-25-009319 Issuance of common stock to Palantir as consideration for settlement agreement, shares 0
0001641172-25-009319 5 43 EQ 0 H Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability Classified To Equity Classified 0001641172-25-009319 Reclassification of warrants from liability classified to equity classified 0
0001641172-25-009319 5 44 EQ 0 H Stock Issued During Period Value Share Based Compensation us-gaap/2024 Issuance of common stock as compensation expense 0
0001641172-25-009319 5 45 EQ 0 H Stock Issued During Period Shares Share Based Compensation us-gaap/2024 Issuance of common stock as compensation expense, shares 0
0001641172-25-009319 5 46 EQ 0 H Stockholders Equity us-gaap/2024 Balances 0
0001641172-25-009319 5 47 EQ 0 H Shares Outstanding us-gaap/2024 Balances, shares 0
0001641172-25-009319 6 2 CF 0 H Net Income Loss us-gaap/2024 Net loss 0
0001641172-25-009319 6 4 CF 0 H Depreciation Depletion And Amortization us-gaap/2024 Depreciation and amortization 0
0001641172-25-009319 6 5 CF 0 H Non Cash Lease Expense 0001641172-25-009319 Non cash lease expense 0
0001641172-25-009319 6 6 CF 0 H Provision For Doubtful Accounts us-gaap/2024 Provision for credit losses 0
0001641172-25-009319 6 7 CF 0 H Provision For Inventory Obsolescence 0001641172-25-009319 Provision for inventory obsolescence 0
0001641172-25-009319 6 8 CF 0 H Fair Value Adjustment Of Warrants us-gaap/2024 Change in fair value of warrant liabilities 0
0001641172-25-009319 6 9 CF 0 H Inventory Impairment Charge 0001641172-25-009319 Inventory impairment 0
0001641172-25-009319 6 10 CF 0 H Goodwill Impairment Loss us-gaap/2024 Goodwill impairment 0
0001641172-25-009319 6 11 CF 0 H Impairment Of Intangible Assets Excluding Goodwill us-gaap/2024 IPR&D impairment 0
0001641172-25-009319 6 12 CF 0 H Employee Benefits And Share Based Compensation us-gaap/2024 Stock-based compensation expense 0
0001641172-25-009319 6 13 CF 0 H Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 us-gaap/2024 Change in fair value of contingent consideration 0
0001641172-25-009319 6 14 CF 0 H Acquired In Process Research And Development 0001641172-25-009319 Acquired in-process research and development 0
0001641172-25-009319 6 15 CF 0 H Issuance Of Common Stock Used In Research And Development 0001641172-25-009319 Issuance of common stock for stem-cells to be used in research and development 0
0001641172-25-009319 6 16 CF 0 H Issuance Of Common Stock As Consideration For Settlement Agreement 0001641172-25-009319 Issuance of common stock to Palantir as consideration for settlement agreement 0
0001641172-25-009319 6 17 CF 0 H Issuance Of Common Stock Relating To Debt Extension And Commitment Fee 0001641172-25-009319 Issuance of common stock to Yorkville for debt extension and SEPA commitment fee 0
0001641172-25-009319 6 18 CF 0 H Issuance Of Common Stock As Compensation Expense 0001641172-25-009319 Issuance of common stock as compensation expense 0
0001641172-25-009319 6 19 CF 0 H Discounts Arising From Loan Arrangement Related Party 0001641172-25-009319 Discounts arising from RWI loan arrangement - related party 0
0001641172-25-009319 6 20 CF 0 H Fair Value Of Warrant Modification For Professional Services 0001641172-25-009319 Fair value of warrant modification for professional services 0
0001641172-25-009319 6 21 CF 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 Loss on debt extinguishment 1
0001641172-25-009319 6 22 CF 0 H Change In Fair Value Of Debt 0001641172-25-009319 Change in fair value of debt 0
0001641172-25-009319 6 23 CF 0 H Change In Fair Value Of Contingent Stock Consideration 0001641172-25-009319 Change in fair value of contingent stock consideration 0
0001641172-25-009319 6 24 CF 0 H Non Cash Interest Expense 0001641172-25-009319 Non cash interest expense 0
0001641172-25-009319 6 25 CF 0 H Increase Decrease In Other Operating Capital Net us-gaap/2024 Other, net 1
0001641172-25-009319 6 27 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable 1
0001641172-25-009319 6 28 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventory 1
0001641172-25-009319 6 29 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other assets 1
0001641172-25-009319 6 30 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0001641172-25-009319 6 31 CF 0 H Increase Decrease In Other Accounts Payable And Accrued Liabilities us-gaap/2024 Accrued expenses and other liabilities 0
0001641172-25-009319 6 32 CF 0 H Increase Decrease In Accrued Research Development Software Expense 0001641172-25-009319 Accrued R&D software 0
0001641172-25-009319 6 33 CF 0 H Increase Decrease In Operating Lease Liability us-gaap/2024 Lease liabilities - operating 0
0001641172-25-009319 6 34 CF 0 H Increase Decrease In Contract With Customer Liability us-gaap/2024 Deferred revenue 0
0001641172-25-009319 6 35 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash used in operating activities 0
0001641172-25-009319 6 37 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Capital expenditures 1
0001641172-25-009319 6 38 CF 0 H Payments To Acquire Other Productive Assets us-gaap/2024 Rebound asset acquisition 1
0001641172-25-009319 6 39 CF 0 H Payments To Acquire In Process Research And Development us-gaap/2024 Purchase of acquired in-process research and development 1
0001641172-25-009319 6 40 CF 0 H Proceeds From Convertible Note 0001641172-25-009319 Proceeds from Sanuwave convertible note 1
0001641172-25-009319 6 41 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash provided by (used in) investing activities 0
0001641172-25-009319 6 43 CF 0 H Proceeds From Warrants And Short Term Debt Related Parties 0001641172-25-009319 Proceeds from warrants and short-term debt - related parties 0
0001641172-25-009319 6 44 CF 0 H Repayments Of Short Term Debt Unaffiliated 0001641172-25-009319 Repayments of short-term debt - unaffiliated 1
0001641172-25-009319 6 45 CF 0 H Proceeds From The Sale Of Common Stock In Atm Offering 0001641172-25-009319 Proceeds from the sale of common stock in ATM offering 0
0001641172-25-009319 6 46 CF 0 H Proceeds From Short Term Debt Unaffiliated 0001641172-25-009319 Proceeds from issuance of short-term debt - unaffiliated 0
0001641172-25-009319 6 47 CF 0 H Payment Of Sepa Commitment Fee 0001641172-25-009319 Payment of SEPA commitment fee 1
0001641172-25-009319 6 48 CF 0 H Repayments Of Short Term Debt Related Party 0001641172-25-009319 Repayments of short-term debt - related parties 1
0001641172-25-009319 6 49 CF 0 H Proceeds From Issuance Of Private Placement us-gaap/2024 Proceeds from PIPE financing 0
0001641172-25-009319 6 50 CF 0 H Proceeds From Stock Options Exercised us-gaap/2024 Proceeds from the exercise of stock options 0
0001641172-25-009319 6 51 CF 0 H Payments Related To Tax Withholding For Share Based Compensation us-gaap/2024 Tax withholding on vesting of restricted stock units 1
0001641172-25-009319 6 52 CF 0 H Proceeds From Issuance Initial Public Offering us-gaap/2024 Proceeds from registered direct offering 0
0001641172-25-009319 6 53 CF 0 H Payments Of Debt Issuance Costs us-gaap/2024 Payments of PIPE and other issuance costs 1
0001641172-25-009319 6 54 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided by financing activities 0
0001641172-25-009319 6 55 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net increase (decrease) in cash, cash equivalents and restricted cash 0
0001641172-25-009319 6 56 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents and restricted cash at beginning of year 0
0001641172-25-009319 6 57 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents and restricted cash at end of year 0
0001641172-25-009319 6 59 CF 0 H Interest Paid Net us-gaap/2024 Cash paid for interest 0
0001641172-25-009319 6 61 CF 0 H Capital Expenditures Incurred But Not Yet Paid us-gaap/2024 Property and equipment included in accounts payable and accrued expenses 1
0001641172-25-009319 6 62 CF 0 H Conversion Of Stock Amount Issued1 us-gaap/2024 Common stock issued for short-term debt conversion 0
0001641172-25-009319 6 63 CF 0 H Modification Of C V Starr Warrants In Connection With Forbearance 0001641172-25-009319 Modification of C.V. Starr warrants in connection with forbearance 0
0001641172-25-009319 6 64 CF 0 H Issuance Of Rwi Warrants In Connection With Forbearance 0001641172-25-009319 Issuance of RWI warrants in connection with forbearance 0
0001641172-25-009319 6 65 CF 0 H Issuance Of Warrants On Senior Secured Bridge Loan 0001641172-25-009319 Issuance of warrants on senior secured bridge loan 0
0001641172-25-009319 6 66 CF 0 H Reduction Of Right Of Use Assets And Associated Lease Liability Due To Lease Modification 0001641172-25-009319 Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification 0
0001641172-25-009319 6 67 CF 0 H P I P E Related Costs Included In Accrued Expenses 0001641172-25-009319 PIPE related costs included in accrued expenses 0
0001641172-25-009319 6 68 CF 0 H Interest Accrued On Senior Secured Loans Within Long Term Debt Related Parties 0001641172-25-009319 Interest accrued on senior secured loans within long-term debt - related parties 0
0001641172-25-009319 6 69 CF 0 H Contingent Consideration Accrued In Connection With Rebound Asset Acquisition 0001641172-25-009319 Contingent consideration accrued in connection with Rebound asset acquisition 0
0001641172-25-009319 6 70 CF 0 H Inventory Acquired In Connection With Rebound Asset Acquisition 0001641172-25-009319 Inventory acquired in connection with Rebound asset acquisition 0
0001641172-25-009319 6 71 CF 0 H Reclassification Of Warrants From Liability Classified To Equity Classified 0001641172-25-009319 Reclassification of warrants from liability classified to equity classified 0
0001641172-25-009319 6 72 CF 0 H Assumption Of Shortterm Debt Unaffiliated By Related Party 0001641172-25-009319 Assumption of short-term debt - unaffiliated by related party 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.